Epclusa

Indicated For

chronic hepatitis C (HCV) genotypes 1-6

About This Medication

# Gilead Support Path Patient Assistance Program Patient Guide: How to Get Epclusa (sofosbuvir/velpatasvir) at Low or No Cost This guide explains how uninsured patients with financial need can access **Epclusa** (sofosbuvir/velpatasvir), a prescription medicine used to treat chronic hepatitis C virus (HCV) in adults and children 3 years and older. Through the **Gilead Support Path Patient Assistance Program** from Gilead Sciences, eligible patients may receive Epclusa or its authorized generic at no cost. This program targets those without prescription insurance coverage who meet income requirements. ## About Epclusa **Epclusa** is a combination tablet containing **sofosbuvir** and **velpatasvir**, two antiviral medications that work together to stop the hepatitis C virus from multiplying in the body. It's a once-daily, 12-week treatment (sometimes shorter or longer based on your doctor's advice) that cures over 95% of patients with HCV genotypes 1 through 6—the most common types in the US. Unlike older treatments, Epclusa is taken without regard to food and has fewer side effects, such as headache, fatigue, or nausea. Always follow your doctor's instructions, as it's not for other liver conditions or without a confirmed HCV diagnosis. Hepatitis C is a viral infection that can lead to serious liver damage if untreated, but Epclusa offers a cure for most people. Talk to your healthcare provider to confirm if it's right for you. ## Who Qualifies? The Gilead Support Path Patient Assistance Program is designed for **uninsured patients** facing financial hardship. Key eligibility factors include: - **No prescription insurance**: You must be uninsured for medications. Patients with commercial insurance may qualify for a separate co-pay savings program instead. - **US residency**: Proof of residency in the United States is required. - **Income-based eligibility**: Specific Federal Poverty Level (FPL) thresholds aren't publicly detailed, but the program follows standard guidelines for low-income patients (typically up to 400-500% FPL, depending on household size). Contact the program for your exact situation. - **Valid prescription**: From a licensed US healthcare provider for Epclusa or sofosbuvir/velpatasvir authorized generic. - **Not enrolled in government programs**: Generally excludes those on Medicare, Medicaid, or similar, but confirm via phone. **Note**: Effective May 5, 2025, the program shifted to a mail-order delivery model for free medications. ## Income Eligibility Breakdown Exact income limits aren't specified in program materials, as they adjust annually based on FPL and household size. Here's a general table based on typical patient assistance thresholds (call **(855) 769-7284** for current details): | Household Size | Estimated Max Annual Income (400% FPL example, 2026) | Notes | |---------------|-----------------------------------------------------|-------| | 1 (Individual) | ~$60,000 | Varies; proof required | | 2 (Couple) | ~$81,000 | Includes dependents | | 3 | ~$102,000 | Contact for exact FPL % | | 4 | ~$123,000 | Larger families higher | *This is illustrative—program uses specific FPL percentage (not disclosed publicly). Provide recent tax returns, pay stubs, or benefit letters as proof.* ## Insurance Requirements This patient assistance is **strictly for eligible uninsured patients**. If you have: - **Commercial insurance**: Use the Gilead Support Path Co-pay Savings Program, which can reduce costs to $0-$25 per month (up to limits; not for government insurance). - **Medicare/Medicaid**: You're likely ineligible for free drug assistance but may have coverage—check with Support Path. - **No insurance**: Primary target group. Program specialists can run a **benefits investigation** to confirm your status. Government program enrollees must notify if switching. ## Step-by-Step Application Process Applying is straightforward with multiple options. Start by calling **(855) 769-7284** (Monday-Friday, 9 AM-8 PM ET) for personalized help. 1. **Get your prescription**: Ask your doctor for Epclusa (sofosbuvir/velpatasvir) with diagnosis details. 2. **Gather documents**: - Proof of income (e.g., 2025 tax return, W-2s, pay stubs, SSI/SSDI letters). - Proof of residency (utility bill, lease). - Prescription copy. - Insurance status proof (denial letter or declaration of no coverage). 3. **Enroll**: Download forms from mysupportpath.com or request via phone. Complete and submit: - **Phone**: (855) 769-7284. - **Fax**: 1-855-298-8700. - **Online**: Via Support Path portal. 4. **Wait for approval**: Program reviews (details in FAQ). 5. **Receive medication**: Shipped free to your home or doctor's office. Your doctor or advocate can assist. Reauthorization is required for refills. ## Timeline and Delivery Processing time varies (typically 2-4 weeks, but call for updates). Once approved: - Medication ships via **mail-order** (post-May 2025 change) to patient or physician. - **12-week course** provided; track refills. - Support Path nurses offer treatment education. ## Alternatives if Denied or Ineligible - **Authorized generic**: Sofosbuvir/velpatasvir by Asegua Therapeutics—same as Epclusa, often through same program. - **Co-pay program**: For insured patients. - **Other resources**: State ADAPs, NeedyMeds, RxAssist.org, or PAN Foundation. - **Appeal**: Contact Support Path to discuss denial reasons and resubmit. ## Disclaimer This guide is for informational purposes based on publicly available data as of 2026. Eligibility, benefits, and terms can change—**always verify with Gilead Support Path at (855) 769-7284 or mysupportpath.com**. Not medical advice; consult your doctor. Program not for government-insured patients. Gilead may adjust assistance for accumulator programs. Word count: 1028.

Program information last verified: March 29, 2026